Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 129Melanoma 90Squamous Cell Carcinoma of Head and Neck 88Breast Neoplasms 70Triple Negative Breast Neoplasms 64Parkinson Disease 4, Autosomal Dominant Lewy Body 45Head and Neck Neoplasms 45Lung Neoplasms 38Ovarian Neoplasms 37Neoplasms 37Neoplasm Metastasis 37Colorectal Neoplasms 37Stomach Neoplasms 36Carcinoma, Renal Cell 34Carcinoma, Transitional Cell 31Pancreatic Neoplasms 29Urinary Bladder Neoplasms 28Carcinoma, Hepatocellular 27Recurrence 21Hodgkin Disease 21Uterine Cervical Neoplasms 20Endometrial Neoplasms 20Prostatic Neoplasms 18Esophageal Neoplasms 18Sarcoma 17Glioblastoma 17Brain Neoplasms 16Fallopian Tube Neoplasms 15Esophageal Squamous Cell Carcinoma 15Carcinoma, Squamous Cell 14

Interventions

Specimen Handling 2Nivolumab 2Magnetic Resonance Spectroscopy 2pembrolizumab 1enfortumab vedotin 1cabozantinib 1Ipilimumab 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Urachal adenocarcinoma × pembrolizumab × Clear all
NCT05756569 2025-07-28

Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology

Emory University

Phase 2 Recruiting
25 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Ureteral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡